What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

siRNA Technology: Mechanisms, Applications, and Challenges

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

RNA interference (RNAi) is a conserved biological process in which double-stranded RNA (dsRNA) triggers sequence-specific silencing of complementary messenger RNA (mRNA) transcripts. Small interfering RNAs (siRNAs) are the synthetic or endogenous 21–23 nucleotide RNA duplexes that harness this pathway for targeted gene knockdown. Since the landmark discovery of RNAi in Caenorhabditis elegans in 1998, siRNA technology has transformed both basic research and therapeutic development, enabling precise interrogation of gene function and offering a platform for treating diseases caused by aberrant gene expression.

Introduction to siRNA Technology

What is siRNA?

Small interfering RNA (siRNA) is a double-stranded RNA molecule, typically 21–23 nucleotides in length, with characteristic 2-nucleotide 3′ overhangs and 5′ phosphate groups. Each strand consists of a guide (antisense) strand that is complementary to the target mRNA and a passenger (sense) strand that is degraded during the silencing process. The guide strand is incorporated into the RNA-induced silencing complex (RISC), where it directs sequence-specific cleavage of complementary mRNA transcripts, thereby preventing translation.

siRNAs can be introduced into cells exogenously as synthetic molecules or generated endogenously from longer dsRNA precursors by the enzyme Dicer. In experimental settings, synthetic siRNAs are the most common tool for transient gene knockdown, offering rapid and potent silencing with well-defined sequence specificity.

Historical context and discovery

The foundation of siRNA technology lies in the discovery of RNAi by Andrew Fire and Craig Mello in 1998. Working with C. elegans, they demonstrated that injecting double-stranded RNA was far more effective at silencing a complementary gene than injecting either sense or antisense single-stranded RNA alone. This observation revealed that dsRNA acts as a potent trigger for sequence-specific gene silencing, a finding that earned Fire and Mello the 2006 Nobel Prize in Physiology or Medicine.

Subsequent work by Thomas Tuschl and colleagues in 2001 showed that synthetic 21-nucleotide siRNA duplexes could induce RNAi in mammalian cells without triggering the non-specific interferon response that longer dsRNA molecules elicit. This breakthrough made siRNA a practical laboratory tool and opened the door to therapeutic applications. The first siRNA-based drug, patisiran (Onpattro), was approved by the U.S. Food and Drug Administration in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis, marking a milestone for the field.

The RNA Interference Pathway

The RNAi pathway can be divided into three principal stages: processing of long dsRNA by Dicer, loading of the guide strand into RISC, and sequence-specific cleavage of target mRNA. Understanding each step is essential for designing effective siRNAs and interpreting knockdown results.

Dicer processing

In the endogenous RNAi pathway, long dsRNA molecules—whether derived from viral replication intermediates, transposons, or experimentally introduced precursors—are recognized by Dicer, an RNase III-family endonuclease. Dicer contains a helicase domain, a PAZ (Piwi-Argonaute-Zwille) domain, and two RNase III domains that together measure and cleave dsRNA at defined intervals.

Dicer binds the end of the dsRNA substrate and processes it processively, generating siRNA duplexes of approximately 21–23 nucleotides with 2-nucleotide 3′ overhangs and 5′ phosphate groups. The PAZ domain anchors the 3′ end of the dsRNA, while the RNase III domains cleave both strands at specific positions relative to this anchor. In mammalian cells, Dicer also interacts with accessory proteins such as TRBP (TAR RNA-binding protein) and PACT (protein activator of protein kinase R), which facilitate substrate recognition and handoff to the RISC loading complex.

For synthetic siRNA applications, Dicer processing is bypassed—the siRNA duplex is introduced directly into the cell. However, some delivery strategies use short hairpin RNA (shRNA) expressed from plasmid or viral vectors, which requires Dicer processing to generate functional siRNAs. The efficiency of Dicer processing can influence the potency of shRNA-based silencing, making the choice of hairpin design critical.

RISC loading and guide strand selection

The siRNA duplex is loaded into the RNA-induced silencing complex (RISC), a multi-protein assembly centered on an Argonaute (Ago) protein. In humans, there are four Argonaute proteins (Ago1–Ago4), but only Ago2 possesses endonucleolytic cleavage activity. Ago2 is the primary effector of siRNA-mediated mRNA cleavage.

Loading occurs through the RISC loading complex (RLC), which includes Dicer, TRBP, and Ago2. The siRNA duplex is unwound, and the strand with the less thermodynamically stable 5′ end is preferentially retained as the guide strand. This asymmetry is determined by the base-pairing stability at the 5′ ends of the two strands: the strand whose 5′ end is less tightly base-paired is more readily unwound and loaded into Ago2. The passenger strand is subsequently cleaved by Ago2 and degraded, or in some cases, unwound and released without cleavage.

The guide strand is positioned within Ago2 such that its 5′ phosphate is anchored in a basic pocket, and the seed region (nucleotides 2–8 from the 5′ end) is pre-organized in an A-form helical conformation. This seed region is critical for initial target recognition, as it nucleates base-pairing with the complementary mRNA sequence.

mRNA targeting and cleavage

The guide strand within Ago2 directs RISC to complementary sequences in target mRNAs. Recognition is initiated by seed region base-pairing, followed by extended base-pairing along the remainder of the guide strand. When the guide strand is fully complementary to the target mRNA, Ago2 cleaves the mRNA between nucleotides 10 and 11 relative to the 5′ end of the guide strand.

Ago2's PIWI domain adopts an RNase H-like fold, with a catalytic tetrad of aspartate and histidine residues coordinating two magnesium ions essential for phosphodiester bond cleavage. The cleaved mRNA fragments are subsequently degraded by cellular exonucleases, rendering the transcript non-functional. Because Ago2 remains bound to the guide strand after cleavage, a single RISC complex can catalyze multiple rounds of mRNA cleavage, providing catalytic silencing.

When the guide strand is only partially complementary to the target—as is common with microRNAs (miRNAs)—Ago2 does not cleave the mRNA. Instead, silencing occurs through translational repression and mRNA deadenylation. This distinction is important: siRNA and miRNA share the same core machinery but achieve silencing through different downstream mechanisms. For siRNA applications, full complementarity is designed to ensure cleavage-mediated knockdown.

Designing Effective siRNAs

The success of an siRNA experiment depends critically on the design of the siRNA sequence. Poorly designed siRNAs can be inactive, non-specific, or immunostimulatory. Several rules have been established to maximize potency and specificity.

Sequence motifs and thermodynamic stability

Effective siRNAs typically share several sequence features. The guide strand should have a 5′ end with relatively weak base-pairing (low GC content) to promote strand selection, while the passenger strand's 5′ end should be more stably paired. This thermodynamic asymmetry biases RISC loading toward the correct strand.

Additional design rules include:

Length: 19–21 base pairs with 2-nucleotide 3′ overhangs (typically dTdT or UU) are standard.
GC content: 30–52% is generally optimal. Extremely high GC content can impede strand unwinding, while very low GC content may reduce target affinity.
Seed region: Avoid sequences with high seed complementarity to unintended transcripts, as this drives off-target silencing.
Target accessibility: The target mRNA region should be accessible—avoiding highly structured regions such as stable stem-loops improves RISC binding.
Position within the gene: Target sequences in the coding region or 3′ untranslated region (UTR) are generally effective. Avoid sequences within 50–100 nucleotides of the start codon or within introns.

For a given gene, multiple siRNAs should be designed and tested, as individual siRNAs can vary substantially in potency. Most commercial design algorithms incorporate these rules and score candidate siRNAs based on predicted efficacy and specificity.

Avoiding off-target effects

Off-target silencing occurs when the guide strand binds to mRNAs with partial complementarity, particularly through seed region matches. This is a major source of false-positive phenotypes in siRNA screens. Several strategies reduce off-target effects:

Sequence selection: Choose siRNAs with minimal seed region complementarity to unintended transcripts. Tools such as BLAST against the transcriptome can identify potential off-targets.
Chemical modifications: Introducing 2′-O-methyl modifications at position 2 of the guide strand reduces seed-mediated off-target silencing without compromising on-target activity.
Use of multiple siRNAs: Phenotypes confirmed with two or more independent siRNAs targeting different regions of the same gene are more likely to reflect true on-target effects.
Rescue experiments: Expressing a siRNA-resistant version of the target gene (with silent mutations in the siRNA binding site) can confirm that the phenotype is due to target knockdown.

Tools for siRNA design

Several web-based tools are widely used for siRNA design, including:

siDirect: Uses a scoring algorithm based on thermodynamic and sequence features.
siRNA Wizard (InvivoGen): Incorporates off-target prediction and provides chemical modification recommendations.
Dharmacon siDESIGN Center: Offers a commercial design tool with extensive validation data.
RNAi Central (Cold Spring Harbor Laboratory): Provides access to multiple design algorithms.

These tools typically require the target mRNA sequence (RefSeq accession or FASTA format) and return a ranked list of candidate siRNAs with predicted efficacy scores. For detailed guidance on selecting and validating siRNAs, see Design siRNA.

Delivery Methods for siRNA

The delivery of siRNA into cells is a major practical hurdle, particularly for in vivo applications. Naked siRNA is rapidly degraded by nucleases in serum, poorly taken up by cells due to its negative charge and size, and can trigger immune responses. Several delivery strategies have been developed to overcome these barriers.

Chemical modifications

Chemical modification of the siRNA backbone improves nuclease resistance and reduces immunostimulation without compromising silencing activity. Common modifications include:

2′-O-methyl (2′-OMe): Increases nuclease stability and reduces immune activation.
2′-fluoro (2′-F): Enhances binding affinity and nuclease resistance.
Phosphorothioate linkages: Replace a non-bridging oxygen with sulfur, increasing resistance to exonucleases.
Locked nucleic acids (LNAs): Contain a methylene bridge between the 2′ oxygen and 4′ carbon, locking the ribose in a C3′-endo conformation and greatly increasing binding affinity.

These modifications are typically incorporated at specific positions—such as the 3′ overhangs and the seed region—to balance stability with silencing activity. Fully modified siRNAs, such as those used in the therapeutic agent inclisiran, can achieve prolonged silencing with infrequent dosing.

Lipid nanoparticles

Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicle for siRNA. LNPs are spherical vesicles composed of ionizable cationic lipids, phospholipids, cholesterol, and polyethylene glycol (PEG)-lipids. The ionizable lipids are positively charged at low pH, facilitating encapsulation of negatively charged siRNA during formulation, but neutral at physiological pH, reducing toxicity.

LNPs deliver siRNA to hepatocytes efficiently because they acquire apolipoprotein E (ApoE) in the bloodstream, which mediates uptake via the low-density lipoprotein receptor (LDLR). Once internalized, the LNP undergoes endosomal escape—a process facilitated by the ionizable lipid's ability to disrupt the endosomal membrane at acidic pH—releasing siRNA into the cytoplasm.

Patisiran, the first approved siRNA drug, uses an LNP formulation targeting transthyretin (TTR) mRNA in hepatocytes. The success of LNPs for hepatic delivery has driven efforts to extend this platform to other tissues, though extrahepatic delivery remains challenging.

Viral vectors and conjugates

Viral vectors, particularly adeno-associated viruses (AAVs) and lentiviruses, can deliver shRNA expression cassettes for sustained silencing. AAV vectors are non-integrating and provide long-term expression in non-dividing cells, while lentiviral vectors integrate into the genome and are suitable for dividing cells. However, viral delivery raises concerns about immunogenicity, insertional mutagenesis, and manufacturing complexity.

Conjugate-based delivery offers an alternative for targeted siRNA delivery. N-acetylgalactosamine (GalNAc) conjugates, which bind the asialoglycoprotein receptor on hepatocytes, have proven highly effective for liver-targeted siRNA delivery. GalNAc-siRNA conjugates, such as inclisiran, are taken up by receptor-mediated endocytosis and achieve potent, durable silencing with subcutaneous administration. Other conjugates, including peptides, aptamers, and antibodies, are under development for extrahepatic targeting.

For a practical overview of transfection methods and optimization, see siRNA Transfection.

Applications of siRNA Technology

siRNA technology has broad applications spanning basic research, therapeutic development, and biotechnology.

Therapeutic applications

The therapeutic potential of siRNA lies in its ability to silence disease-causing genes with high specificity. Approved siRNA drugs include:

Patisiran (Onpattro): Targets TTR mRNA for the treatment of hereditary transthyretin amyloidosis, a condition caused by accumulation of misfolded transthyretin protein.
Givosiran (Givlaari): Targets aminolevulinate synthase 1 (ALAS1) mRNA for acute hepatic porphyria.
Lumasiran (Oxlumo): Targets hydroxyacid oxidase 1 (HAO1) mRNA for primary hyperoxaluria type 1.
Inclisiran (Leqvio): Targets proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA for hypercholesterolemia.

These drugs exploit the natural tropism of LNPs and GalNAc conjugates for hepatocytes, where the target genes are expressed. Ongoing clinical trials are exploring siRNA therapies for conditions including hypertension, hepatitis B, and various cancers. The siRNA Drug landscape continues to expand as delivery technologies improve.

Functional genomics

siRNA-mediated knockdown is a cornerstone of functional genomics, enabling systematic loss-of-function screens to identify genes involved in specific biological processes. High-throughput siRNA libraries targeting the entire human genome or specific gene families can be screened in cell-based assays to identify genes required for cell viability, proliferation, migration, or response to drugs.

These screens have identified novel drug targets, revealed genetic dependencies in cancer cells, and mapped signaling pathways. The combination of siRNA screening with high-content imaging and computational analysis has accelerated the pace of gene function discovery. For detailed protocols on knockdown validation, see siRNA Knockdown.

Agricultural and veterinary uses

RNAi-based approaches are being developed for crop protection and pest control. Transgenic plants expressing dsRNA targeting essential genes in insect pests can confer resistance to herbivory. Similarly, RNAi sprays containing dsRNA can be applied to crops to silence pest genes. In veterinary medicine, siRNA-based therapies are being explored for viral infections and inflammatory diseases in livestock.

siRNA vs. Other Gene Silencing Tools

Several technologies can silence gene expression, each with distinct advantages and limitations. Choosing the right tool depends on the experimental question, the duration of silencing required, and the target cell type.

Tool	Mechanism	Duration	Advantages	Limitations
siRNA	Direct RISC loading, mRNA cleavage	Transient (3–7 days)	Rapid, potent, easy to deliver	Short duration, off-target effects
shRNA	Vector-based, Dicer processing	Stable (weeks–months)	Sustained silencing, inducible options	Requires cloning, viral delivery
Antisense oligonucleotides (ASOs)	RNase H-mediated mRNA degradation	Transient	Can target nuclear RNAs, splice modulation	Less potent, requires high doses
CRISPR-Cas9	Genomic DNA editing	Permanent	Gene knockout or correction	Off-target editing, requires delivery of large constructs

shRNA and vector-based RNAi

Short hairpin RNA (shRNA) is expressed from a DNA template, typically delivered via plasmid or viral vectors. The hairpin transcript is processed by Dicer into functional siRNA. shRNA provides sustained silencing, making it suitable for long-term experiments and therapeutic applications requiring durable knockdown. However, shRNA requires cloning and delivery of a DNA construct, which is more labor-intensive than synthetic siRNA. Inducible shRNA systems, such as those using the tetracycline-responsive promoter, allow temporal control of silencing.

Antisense oligonucleotides

Antisense oligonucleotides (ASOs) are single-stranded DNA or RNA molecules, typically 15–20 nucleotides long, that bind complementary mRNA through Watson-Crick base-pairing. ASOs can recruit RNase H to cleave the target mRNA or sterically block translation or splicing. Unlike siRNA, ASOs do not require the RNAi machinery and can target nuclear transcripts. ASOs are chemically modified (e.g., phosphorothioate, 2′-O-methoxyethyl) to enhance stability and delivery. They are particularly useful for modulating splicing, a function that siRNA cannot perform.

CRISPR-Cas9

CRISPR-Cas9 is a genome-editing tool that introduces permanent changes to the DNA sequence. Unlike siRNA, which silences gene expression transiently at the mRNA level, CRISPR-Cas9 can generate complete gene knockouts by introducing insertions or deletions that disrupt the open reading frame. CRISPR is the tool of choice when permanent gene disruption is required, but it is not suitable for studying essential genes in proliferating cells, where knockout is lethal. In such cases, siRNA-mediated knockdown provides a viable alternative because it reduces—but does not eliminate—gene expression.

Challenges and Limitations of siRNA

Despite its power, siRNA technology faces several challenges that can confound experiments and limit therapeutic application.

Off-target silencing

Off-target effects are a primary concern in siRNA experiments. The guide strand can silence mRNAs with partial complementarity, particularly through seed region matches (nucleotides 2–8). A single siRNA can therefore affect the expression of hundreds of unintended transcripts. These off-target effects are often cell-type specific and can produce phenotypes unrelated to the intended target.

Mitigation strategies include using chemically modified siRNAs that reduce seed-mediated silencing, employing multiple independent siRNAs per gene, and validating phenotypes with rescue experiments. Genome-wide expression profiling can identify off-target signatures, though this is impractical for routine experiments.

Innate immune response

Exogenous RNA can activate innate immune sensors, including Toll-like receptors (TLRs) 3, 7, and 8, and cytosolic sensors such as RIG-I and MDA5. Activation of these pathways triggers type I interferon production and inflammatory cytokine secretion, which can alter gene expression and confound experimental results. The immunostimulatory activity of siRNA depends on sequence motifs (e.g., GU-rich sequences) and the delivery vehicle.

Chemical modifications, particularly 2′-O-methylation of the guide strand, suppress immune activation. Purification of siRNAs to remove contaminating dsRNA byproducts from chemical synthesis also reduces immunostimulation.

Stability and biodistribution

Naked siRNA has a half-life of minutes in serum due to nuclease degradation and rapid renal clearance. Chemical modifications improve stability, but biodistribution remains a challenge: systemically administered siRNA accumulates primarily in the liver and kidneys, with poor uptake in other tissues. Crossing the blood-brain barrier is particularly difficult, limiting siRNA applications for neurological diseases.

Delivery vehicles such as LNPs and GalNAc conjugates address these issues for hepatic targets, but extrahepatic delivery remains an active area of research. Local delivery routes—intravitreal injection for ocular diseases, intranasal delivery for respiratory conditions, and intratumoral injection for cancer—can bypass systemic barriers.

Studying siRNA: Experimental Approaches

Validating siRNA activity and specificity requires careful experimental design and appropriate controls.

Positive and negative controls

Every siRNA experiment should include:

Non-targeting negative control: A scrambled siRNA with no complementarity to any known mRNA. This controls for non-specific effects of transfection and immune stimulation.
Positive control: A siRNA targeting a well-characterized gene (e.g., GAPDH or cyclophilin B) to confirm that the transfection and silencing machinery are functional.
Untreated or mock-transfected cells: Controls for the effect of the transfection reagent alone.

For phenotype-based assays, a rescue experiment—expressing a siRNA-resistant version of the target gene—provides the strongest evidence that the phenotype is due to on-target silencing.

Quantitative RT-PCR and Western blot

Knockdown efficiency should be measured at both the mRNA and protein levels. Quantitative reverse transcription PCR (qRT-PCR) is the standard method for mRNA quantification. Total RNA is extracted, reverse-transcribed using oligo(dT) or random hexamer primers, and amplified with gene-specific primers and a fluorescent probe (TaqMan) or intercalating dye (SYBR Green). The threshold cycle (Ct) values are normalized to a reference gene (e.g., GAPDH, ACTB, or HPRT1) using the 2^(-ΔΔCt) method.

Western blotting confirms that mRNA knockdown translates to reduced protein levels. Protein lysates are separated by SDS-PAGE, transferred to a membrane, and probed with a target-specific antibody. The timing of protein analysis is important: because proteins have varying half-lives, the optimal time point for detecting knockdown may differ from the mRNA peak effect.

High-throughput screening

High-throughput siRNA screens use automated liquid handling and high-content imaging to assess phenotypes across thousands of genes. Libraries are typically arrayed in 96- or 384-well plates, with each well containing a single siRNA. After transfection and incubation, cells are fixed and stained for markers of interest, and images are analyzed using automated microscopy and image analysis software.

Screens require rigorous quality control, including assessment of transfection efficiency, plate-to-plate variability, and hit confirmation with independent siRNAs. The siRNA and miRNA comparison is particularly relevant in screening contexts, as miRNA-like off-target effects can confound hit identification.

Common Pitfalls and Best Practices

Students and researchers frequently encounter the following issues when working with siRNA. Awareness of these pitfalls improves experimental reliability.

Avoiding non-specific effects

The most common mistake is attributing a phenotype to the intended target when it actually results from off-target silencing or immune stimulation. To avoid this:

Always use at least two independent siRNAs targeting different regions of the gene.
Include a non-targeting control and, ideally, a rescue experiment.
Use chemically modified siRNAs to reduce off-target effects.
Confirm knockdown at both mRNA and protein levels.

Optimizing transfection

Transfection efficiency is a major determinant of knockdown efficacy. Poor transfection leads to weak silencing and variable results. Optimize the following parameters for each cell type:

Cell density: Typically 30–50% confluency at transfection for adherent cells.
siRNA concentration: 1–50 nM is typical; higher concentrations increase off-target effects and toxicity.
Transfection reagent: Lipid-based reagents (e.g., Lipofectamine RNAiMAX) work well for most cell lines, but primary cells and suspension cells may require specialized reagents or electroporation.
Serum and antibiotics: Some transfection reagents require serum-free conditions during transfection.

For hard-to-transfect cells, alternative methods such as electroporation or viral delivery of shRNA may be necessary.

Interpreting results correctly

A common error is assuming that mRNA knockdown directly correlates with protein knockdown. mRNA and protein half-lives differ, and the timing of analysis matters. For a protein with a long half-life, mRNA knockdown may not produce a detectable protein reduction for several days. Conversely, measuring protein too late may miss the effect if the protein is rapidly turned over.

Another pitfall is ignoring the biological context. siRNA-mediated knockdown is rarely complete—residual protein expression may be sufficient to maintain function. If the phenotype is weak or absent, consider whether the residual protein level is below the threshold required for the phenotype.

Frequently Asked Questions

What is siRNA technology?

siRNA technology is a method for sequence-specific gene silencing using small interfering RNAs, which are 21–23 nucleotide double-stranded RNA molecules. The guide strand of the siRNA is loaded into the RNA-induced silencing complex (RISC), where it directs cleavage of complementary mRNA, preventing translation. This technology is widely used in research to study gene function and in medicine to treat diseases caused by pathogenic gene expression.

How does siRNA silence genes?

siRNA silences genes through the RNA interference pathway. The siRNA duplex is loaded into RISC, and the guide strand is retained while the passenger strand is degraded. The guide strand base-pairs with complementary mRNA, and the Argonaute 2 protein within RISC cleaves the mRNA between nucleotides 10 and 11 relative to the guide strand's 5′ end. The cleaved mRNA is degraded, preventing protein synthesis.

What are the main applications of siRNA technology?

siRNA technology is used for functional genomics, where it enables systematic loss-of-function screens to identify genes involved in biological processes. Therapeutically, siRNA drugs have been approved for conditions including hereditary transthyretin amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia. Additional applications include agricultural pest control and veterinary medicine.

What are the challenges of using siRNA?

Key challenges include off-target silencing, where the guide strand silences unintended mRNAs through partial complementarity; immune stimulation, where exogenous RNA activates innate immune sensors; and delivery barriers, particularly for extrahepatic tissues. Chemical modifications and advanced delivery vehicles such as lipid nanoparticles and GalNAc conjugates address some of these challenges.

How is siRNA delivered into cells?

siRNA can be delivered by chemical transfection using lipid-based reagents, electroporation, or viral vectors expressing shRNA. For in vivo applications, lipid nanoparticles and GalNAc conjugates are the most clinically advanced platforms, enabling efficient delivery to hepatocytes. Local delivery routes are used for ocular, respiratory, and intratumoral applications.

What is the difference between siRNA and shRNA?

siRNA is a synthetic double-stranded RNA molecule introduced directly into cells, providing transient silencing that lasts several days. shRNA is a short hairpin RNA expressed from a DNA template delivered by plasmid or viral vectors. shRNA is processed by Dicer into functional siRNA and provides sustained silencing. The choice depends on the required duration of knockdown and the experimental system.

How do I design an effective siRNA?

Effective siRNA design requires selecting a 19–21 nucleotide sequence with 30–52% GC content, weak 5′ base-pairing on the guide strand, and minimal seed region complementarity to unintended transcripts. Use web-based design tools that incorporate thermodynamic and specificity rules, and validate each siRNA with multiple independent sequences and appropriate controls.

Key Takeaways

siRNA technology enables sequence-specific gene silencing through the RNA interference pathway, with the guide strand directing Ago2-mediated cleavage of complementary mRNA.
Effective siRNA design requires attention to thermodynamic asymmetry, GC content, seed region specificity, and target accessibility, with multiple siRNAs per gene recommended.
Delivery remains a major challenge; chemical modifications, lipid nanoparticles, and GalNAc conjugates are the most effective solutions for in vivo applications.
siRNA provides transient knockdown, whereas shRNA offers sustained silencing, ASOs can modulate splicing, and CRISPR-Cas9 produces permanent genetic changes.
Off-target effects and immune stimulation are the principal sources of false phenotypes; rigorous controls, including non-targeting siRNAs and rescue experiments, are essential.
Approved siRNA drugs demonstrate the therapeutic potential of this technology, particularly for liver-targeted diseases.
Validation of knockdown requires both mRNA quantification by qRT-PCR and protein analysis by Western blot, with attention to the timing of each measurement.